Clinical trial
Abciximab in Patients Undergoing Percutaneous Coronary Intervention for…
NCT00420030 · Charles University, Czech Republic, Other · Completed
Key facts
| NCT number | NCT00420030 |
|---|---|
| Title | Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock |
| Official title | Routine Upfront Abciximab Versus Standard Peri-Procedural Therapy in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock PRAGUE-7 Trial. |
| Lead sponsor | Charles University, Czech Republic, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Shock, Cardiogenic |
| Intervention type | Drug |
| Interventions | Abciximab |
| Enrollment | 80 |
| Start date | Sep 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Jan 9, 2007 |
| Last update posted | Jun 23, 2009 |
| Countries | Czechia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: